Product Program year 2025 Source: CMS Open Payments

Eovist

Drug Radiology

NDC 50419-320-05

Open in the dashboard

General payments

$118,950

147 payments

Research payments

$1,098,604

27 payments

Through program year 2025, $118,950 in general payments and $1,098,604 in research payments were reported against Eovist (Radiology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

13 rows
Year Kind Amount Payments
2025 General $461 6
2025 Research $146,590 4
2024 General $35 1
2024 Research $84,246 4
2023 General $24,463 30
2023 Research $68,577 4
2022 General $16,398 18
2022 Research $653,296 7
2021 General $18,819 27
2021 Research $44,705 3
2020 General $18,832 6
2020 Research $101,190 5
2019 General $39,942 59

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $93,991 110 payments
  2. Bayer Healthcare LLC $24,959 37 payments
Top recipients General payments · program year 2025
  1. Bachir Taouli Diagnostic Radiology · New York, NY $230 50% · 3 payments
  2. Christopher Comstock Diagnostic Radiology · San Diego, CA $97 21% · 1 payment
  3. Alexander Kagen Diagnostic Radiology · New York, NY $73 16% · 1 payment
  4. Barak Friedman Diagnostic Radiology · New Hyde Park, NY $61 13% · 1 payment

Each share is of general payments naming this product in 2025.

Specialties paid General payments · program year 2025
  1. Diagnostic Radiology Radiology $461 100% · 4 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. New York $364 79% · 3 recipients
  2. California $97 21% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Eovist
Billing code Providers Services Paid by Medicare
Injection, gadoxetate disodium, 1 ml A9581 170 61,488 $689,757

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

147 general · 27 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record